Owlstone Medical secures $6.5 million to support development of breath-based diagnostics for infectious disease Post author: Post published:April 25, 2024 Post category:uncategorized Funding represents the first time the foundation has taken an equity position in a breath diagnostics company. You Might Also Like New MS research harnessing the brain’s healing power March 5, 2025 Expert explores the expanding applications of GLP1 therapies November 28, 2024 AmoyDx® Pan Lung Cancer PCR Panel approved in Japan as a companion diagnostic for Haiyitan® tablets (gumarontinib) August 23, 2024
AmoyDx® Pan Lung Cancer PCR Panel approved in Japan as a companion diagnostic for Haiyitan® tablets (gumarontinib) August 23, 2024